CLINICAL TRIALS PROFILE FOR MYCOBUTIN

All Clinical Trials for Mycobutin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002343 ↗	A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS	Completed	Pharmacia	Phase 4	1969-12-31	To optimize Mycobacterium avium Complex (MAC) prophylaxis in AIDS patients by measuring serum rifabutin levels and adjusting the dose accordingly. To combine rifabutin with ethambutol to examine the effect of combination therapy in preventing or delaying the incidence of MAC bacteremia in this patient population.
NCT00598897 ↗	Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease	Completed	Abbott	Phase 4	1995-08-01	To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598897 ↗	Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease	Completed	Pfizer	Phase 4	1995-08-01	To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598897 ↗	Use of Clarithromycin and Rifabutin for the Treatment of M. Avium Complex (MAC) Lung Disease	Completed	The University of Texas Health Science Center at Tyler	Phase 4	1995-08-01	To determine the safety and tolerance of clarithromycin given three times per week in combination with multiple drugs including rifabutin three times per week
NCT00598962 ↗	Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease	Completed	Pfizer	Phase 4	1994-12-01	To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
NCT00598962 ↗	Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease	Completed	The University of Texas Health Science Center at Tyler	Phase 4	1994-12-01	To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
NCT00810407 ↗	Safety And Efficacy Of Rifabutin In Patients For Non-HIV Patients	Completed	Pfizer		2008-11-01	The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Clinical Trial Conditions for Mycobutin

Condition Name

Condition Name for Mycobutin
Intervention	Trials
Tuberculosis	3
Non-tuberculous Mycobacterial Diseases (Including MAC Disease)	2
HIV Infections	2
Healthy	1

Condition MeSH

Condition MeSH for Mycobutin
Intervention	Trials
Mycobacterium Infections	5
HIV Infections	4
Mycobacterium avium-intracellulare Infection	4
Infection	3

Clinical Trial Locations for Mycobutin

Trials by Country

Trials by Country for Mycobutin
Location	Trials
United States	3
South Africa	1
Italy	1
Australia	1
Uganda	1

Trials by US State

Trials by US State for Mycobutin
Location	Trials
Texas	2
California	1

Clinical Trial Progress for Mycobutin

Clinical Trial Phase

Clinical Trial Phase for Mycobutin
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	1
Phase 2	2

Clinical Trial Status

Clinical Trial Status for Mycobutin
Clinical Trial Phase	Trials
Completed	7
Unknown status	2
Recruiting	1

Clinical Trial Sponsors for Mycobutin

Sponsor Name

Sponsor Name for Mycobutin
Sponsor	Trials
Pfizer	4
Boehringer Ingelheim	2
Abbott	2

Sponsor Type

Sponsor Type for Mycobutin
Sponsor	Trials
Industry	9
Other	7